5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

Imatinib Mesylate

Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)

Trial Locations (1)

RECRUITING

Asan Medical Center, University of Ulsan College of Medicine, Seoul